Catalent, Inc. CTLT
We take great care to ensure that the data presented and summarized in this overview for Catalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CTLT
View all-
Vanguard Group Inc Valley Forge, PA20.4MShares$1.15 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$853 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA12.9MShares$726 Million0.12% of portfolio
-
Nomura Holdings Inc Tokyo, M011.3MShares$632 Million1.65% of portfolio
-
Janus Henderson Group PLC London, X09.56MShares$537 Million0.3% of portfolio
-
State Street Corp Boston, MA7.42MShares$417 Million0.02% of portfolio
-
Veritas Asset Management LLP6.03MShares$338 Million2.85% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.14MShares$289 Million0.04% of portfolio
-
Barclays PLC London, X04.77MShares$268 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA4.17MShares$234 Million0.02% of portfolio
Latest Institutional Activity in CTLT
Top Purchases
Top Sells
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Insider Transactions at CTLT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 04
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
1,401
-6.36%
|
$75,654
$54.26 P/Share
|
Mar 15
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
387
-1.29%
|
$21,672
$56.2 P/Share
|
Jan 25
2024
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.78%
|
$26,150
$50.41 P/Share
|
Jan 16
2024
|
Michael Hatzfeld Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,908
+46.71%
|
-
|
Dec 08
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
250
-0.83%
|
$9,250
$37.18 P/Share
|
Dec 08
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,023
+3.28%
|
-
|
Dec 08
2023
|
Alessandro Maselli President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-2.14%
|
$71,188
$37.18 P/Share
|
Dec 08
2023
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,761
+4.02%
|
-
|
Dec 08
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Payment of exercise price or tax liability
|
Direct |
367
-0.38%
|
$13,579
$37.18 P/Share
|
Dec 08
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
1,505
+1.53%
|
-
|
Dec 08
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Payment of exercise price or tax liability
|
Direct |
256
-1.15%
|
$9,472
$37.18 P/Share
|
Dec 08
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
747
+3.24%
|
-
|
Oct 27
2023
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+19.94%
|
-
|
Oct 27
2023
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+34.31%
|
-
|
Oct 27
2023
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+20.31%
|
-
|
Oct 27
2023
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+47.56%
|
-
|
Oct 27
2023
|
Karen Flynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+22.32%
|
-
|
Oct 27
2023
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+22.66%
|
-
|
Oct 27
2023
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+13.9%
|
-
|
Oct 27
2023
|
Frank A Damelio Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+46.73%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 290K shares |
---|---|
Open market or private purchase | 22K shares |
Open market or private sale | 12.5K shares |
---|---|
Payment of exercise price or tax liability | 4.59K shares |